Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control.

ABSTRACT:

Objective

Optimal glycemic control slows diabetic retinopathy (DR) development and progression and is the standard of care for type 1 diabetes. However, these glycemic goals are difficult to achieve and sustain in clinical practice. The Renin Angiotensin System Study (RASS) showed that renin-angiotensin system (RAS) blockade can slow DR progression. In the current study, we evaluate whether glycemic control influenced the benefit of RAS blockade on DR progression in type 1 diabetic patients.

Research design and methods

We used RASS data to analyze the relationships between two-steps or more DR progression and baseline glycemic levels in 223 normotensive, normoalbuminuric type 1 diabetic patients randomized to receive 5 years of enalapril or losartan compared with placebo.

SUBMITTER: Harindhanavudhi T 

PROVIDER: S-EPMC3142059 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature